pfront abiraterone and docetaxel administration in patients with high-risk metastatic hormone-naive prostate cancer
Not Applicable
- Conditions
- Metastatic prostate cancer without initial treatment
- Registration Number
- JPRN-UMIN000021079
- Lead Sponsor
- Department of Urology, Akita University School of Medicine
- Brief Summary
pfront ABI provided better CRPC-free survival than upfront DOC; however, no significant differences in PFS2 or OS were observed between the two groups. Personalized management based on prognostic risk factors may benefit patients with mCSPC treated with upfront intensified therapies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 301
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who meet the criteria below will be excluded: 1.Severe cardiovascular disease and diabetes mellitus 2.Chronic pulmonary disease 3.Allergy to taxanes 4. Active concomitant malignancy 5. Difficulty of understanding of the trial because of mental disease 6.Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Disease specific survival, overall survival, safety, QOL, pain score, symptomatic skeletal event